Amlitelimab - Sanofi
Alternative Names: KY-1005; SAR-445229Latest Information Update: 03 Feb 2026
At a glance
- Originator Kymab
- Developer Kymab; Sanofi
- Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action OX40 ligand inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Atopic dermatitis
- Phase II Asthma
- Discontinued Alopecia areata; Coeliac disease; Graft-versus-host disease; Hidradenitis suppurativa; Systemic scleroderma
Most Recent Events
- 23 Jan 2026 Sanofi plans to submit a regulatory application for Atopic dermatitis in the second half of 2026
- 23 Jan 2026 Adverse events data from a phase III SHORE trial in Atopic dermatitis released by Sanofi
- 23 Jan 2026 Efficacy and adverse events data from a phase II ATLANTIS trial in Atopic dermatitis released by Sanofi